Category: Neurology
Keywords: tPA, stroke, intracerebral hemorrhage (PubMed Search)
Posted: 3/19/2008 by Aisha Liferidge, MD
(Updated: 10/31/2024)
Click here to contact Aisha Liferidge, MD
Category: Critical Care
Keywords: phosphate, hypotension, hypomagnesemia (PubMed Search)
Posted: 3/18/2008 by Mike Winters, MBA, MD
(Updated: 10/31/2024)
Click here to contact Mike Winters, MBA, MD
Potassium Phosphate ("K-phos")
Over the weekend, I had a patient with Dr. Scott that had a phosphate of 0.8 mmol/L. Phosphate < 1.0 mmol/L is an indication for IV repletion. IV repletion involves giving potassium phosphate. An important clinical question, therefore, is how much potassium does the patient actually get?
Category: Cardiology
Keywords: cardiogenic shock, hypertrophic cardiomyopathy (PubMed Search)
Posted: 3/17/2008 by Amal Mattu, MD
(Updated: 10/31/2024)
Click here to contact Amal Mattu, MD
Cardiogenic shock associated with LV outflow obstruction is managed best without the use of vasoconstrictive agents and vasopressors. Ideally, patients should be treated with IVF and beta blockade. Alpha agonists (e.g. ISO) can also be added.
Typical vasopressors may actually worsen LV outflow obstruction in these patients.
Category: ENT
Keywords: Avulsed Tooth, hanks solution, dental emergencies (PubMed Search)
Posted: 3/16/2008 by Michael Bond, MD
(Updated: 10/31/2024)
Click here to contact Michael Bond, MD
Dental Emergency -- Avulsed Tooth
Category: Pediatrics
Keywords: Gonorrhea, Chlamydia, Syphilis, Sexual Abuse, Trichomonas (PubMed Search)
Posted: 3/14/2008 by Sean Fox, MD
(Updated: 10/31/2024)
Click here to contact Sean Fox, MD
Sexual Abuse
Category: Toxicology
Keywords: sumatriptan, myocardial infarction, migraine (PubMed Search)
Posted: 3/13/2008 by Fermin Barrueto
(Updated: 10/31/2024)
Click here to contact Fermin Barrueto
Category: Neurology
Keywords: benign paroxsymal positional vertigo, vertigo, bppv, dix hallpike maneuver, dizziness (PubMed Search)
Posted: 3/12/2008 by Aisha Liferidge, MD
(Updated: 1/9/2010)
Click here to contact Aisha Liferidge, MD
Category: Gastrointestional
Keywords: Variceal Bleed (PubMed Search)
Posted: 3/11/2008 by Rob Rogers, MD
(Updated: 10/31/2024)
Click here to contact Rob Rogers, MD
Medical Regimen for Suspected Variceal Bleed
To review what Dr. Bond and Dr. Winters have already posted:
Three medical therapies have been shown to be effective in patients with severe upper GI bleed thought to be due to esophageal varices:
Most of our gastroenterologists recommend this regimen (all three therapies)
Other things to consider:
Category: Critical Care
Keywords: fresh frozen plasma, coagulopathy, PRBC (PubMed Search)
Posted: 3/11/2008 by Mike Winters, MBA, MD
(Updated: 10/31/2024)
Click here to contact Mike Winters, MBA, MD
Coagulopathy and Trauma
Category: Cardiology
Keywords: MI, Cardiogenic Sock (PubMed Search)
Posted: 3/8/2008 by Michael Bond, MD
(Emailed: 3/9/2008)
(Updated: 10/31/2024)
Click here to contact Michael Bond, MD
Post-MI cardiogenic shock, while traditionally thought to carry a mortality > 80%, actually has perhaps half that mortality when patients are treated aggressively with prompt invasive therapy (PCI, possibly CABG). Fibrinolytics have traditionally been discouraged, but authors now indicate that they should be given if all of the following three conditions are present:
Sent on behalf of Dr. Amal Mattu
[adapted from: Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008;117:686-697.]
Category: ENT
Keywords: Trigeminal Neuralgia, Microvascular decompression, treatment (PubMed Search)
Posted: 3/8/2008 by Michael Bond, MD
(Updated: 10/31/2024)
Click here to contact Michael Bond, MD
Trigeminal Neuralgia
Category: Pediatrics
Keywords: Appendicitis, Delayed Surgical intervention, Perforation (PubMed Search)
Posted: 3/7/2008 by Sean Fox, MD
(Updated: 10/31/2024)
Click here to contact Sean Fox, MD
Acute Appendicitis – Delayed Surgery option?
Category: Toxicology
Keywords: amiodarone, torsades, hypothyroidism, toxicity, adverse effects, medication induced (PubMed Search)
Posted: 3/6/2008 by Ellen Lemkin, MD, PharmD
(Updated: 10/31/2024)
Click here to contact Ellen Lemkin, MD, PharmD
Did you know how many toxicities and adverse effects amiodarone has? Many are severe, and many VERY common.
1. CARDIAC: hypotension with rapid infusion, prolonged QT, torsades
2. NEUROLOGIC problems occur in 20-40%, including malaise, ataxia, and peripheral neuropathies
3. ENDOCRINE: hypothyroidism and hyperthyroidism
4. GI problems occur in 25%
5. OPHTHALMOLOGIC disturbances include optic neuropathy, papilledema, and photosensitivity
6. SKIN: blue grey pigmentation
7. PULMONARY: pulmonary fibrosis
Category: Neurology
Keywords: nystagmus, cerebellar dysfunction (PubMed Search)
Posted: 3/6/2008 by Aisha Liferidge, MD
(Updated: 10/31/2024)
Click here to contact Aisha Liferidge, MD
Category: Critical Care
Keywords: aspiration pneumonitis (PubMed Search)
Posted: 3/4/2008 by Mike Winters, MBA, MD
(Updated: 10/31/2024)
Click here to contact Mike Winters, MBA, MD
Aspiration Pneumonitis
Category: Misc
Keywords: Oncologic, Emergency, SVC Syndrome (PubMed Search)
Posted: 3/3/2008 by Rob Rogers, MD
(Updated: 10/31/2024)
Click here to contact Rob Rogers, MD
Clinical Presentation of SVC Syndrome
SVC syndrome (caused either by tumor or thrombosis of the SVC) classically presents with facial swelling, arm swelling, and dilated chest wall veins. The problem in the real world is that often times the manifestaions are a bit more subtle.
Some SVC syndrome pearls:
Category: Cardiology
Keywords: cardiogenic shock, right ventricular failure, myocardial infarction (PubMed Search)
Posted: 3/2/2008 by Amal Mattu, MD
(Updated: 10/31/2024)
Click here to contact Amal Mattu, MD
Right ventricular (RV) dysfunction in the setting of acute MI accounts for only 5% of cases of cardiogenic shock but carries nearly the same mortality as LV shock. Shock due to RV dysfunction is usually treated by aggressive volume loading with IVF. However...
In some cases of RV dysfunction, RV end-diastolic pressure can be very high, resulting in shiftng of the invterventricular septum into the LV cavity, which in turn decreases LV filling and cardiac output. Aggressive fluid resuscitation in these patients may actually further worsen RV pressures, leading to further reductions in cardiac output. These patients should instead be treated early with vasopressors.
How do you tell if your patient needs aggressive fluid resuscitation or early vasopressors? Bedside ultrasound can be the answer...if you find marked distension of the RV, go with early vasopressors. If the RV appears normal in size (smaller than LV), go with the IVF.
And of course early revascularization is critical as well.
(adapted from: Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008;117:686-697.)
Category: Infectious Disease
Keywords: meningitis, fluoroquinolone (PubMed Search)
Posted: 2/25/2008 by Michael Bond, MD
(Emailed: 3/1/2008)
(Updated: 10/31/2024)
Click here to contact Michael Bond, MD
It has become standard that close contacts of individuals being treated for bacterial meningitis be treated prophalacticly with antibiotics to prevent additional cases. Fluoroquinolones, in particular ciprofloxicin, have been the drug of choice as a single dose provided adequate protection.
Now the CDC is reporting the first cluster of fluoroquinolone-resistant meningococcal disease in North America have been documented along the Minnesota-North Dakota border. As of now, the CDC still recommends ciprofloxacin for all parts of the country except for a 34-county area in the Minnesota-North Dakota area. In that area the CDC is recommending rifampin, ceftriaxone or azithromycin be used.
This needs to be followed closely as the resistant organism is extremely likely to spread across the country and it will probably this time next year when nobody can use ciprofloxacin anymore.
Category: Pediatrics
Keywords: Delayed Umbilical Cord Separation, Omphalitis, Leukocyte Adhesion Deficiency (PubMed Search)
Posted: 2/29/2008 by Sean Fox, MD
(Updated: 10/31/2024)
Click here to contact Sean Fox, MD
Umbilical Cord Problems
Category: Critical Care Literature Update
Keywords: hydrocortisone, corticosteroids, insulin, sepsis (PubMed Search)
Posted: 2/28/2008 by Mike Winters, MBA, MD
(Updated: 10/31/2024)
Click here to contact Mike Winters, MBA, MD
Since all of us are taking care of critically ill patients for longer periods of time, I think it is important to be familar with current critical care literature. Often, we are the first "intensivist" a patient sees when they arrive to the hospital. To keep us up to date, I am going to be sending out critical care literature updates every couple of weeks similar to Amal's cardiology updates. Please email me with any questions, comments, or feedback.
Mike
Recent Articles from the 2008 Critical Care Literature
Hydrocortisone therapy for patients with septic shock.
Sprung CL, Annane D, Keh D,
Corticosteroid therapy for patients with septic shock seems to change favor every couple of years. In the first publication of the Surviving Sepsis Campaign Guidelines, steroids were given a favorable recommendation based largely upon the results of one multicenter, randomized, controlled trial. (Annane, et al. JAMA 2002;288:862-71) In this study, Annane reported a reduction in the likelihood of death in patients who did not respond to the corticotropin stimulation test and were given steroids (hydrocortisone and fludrocortisone).
The current study is from the CORTICUS Study Group and is a multicenter, randomized, double-blind, placebo-controlled study conducted in 52 ICUs from March 2002 to November 2005. Enrolled patients had to have clinical evidence of infection, a systemic response to infection, organ dysfunction attributable to sepsis, and the onset of shock within 72 hours (SBP < 90 mmHg despite fluids or vasopressors). Patients were randomized to receive either hydrocortisone or placebo for 5 days. Doses were then tapered over the next 6 days for a total duration of therapy of 11 days. A lack of response to corticotropin was defined as an increase in cortisol of no more then 9 mcg/dL. The primary end point of the study was the rate of death from any cause at 28 days in “non-responders”. Some important secondary end-points included the rate of death at 28 days in “responders”, time to reversal of shock, duration of ICU and hospital stay, and rates of death at 1 year.
Four-hundred ninety nine patients were enrolled in the study. Of these, 233 were identified as “non-responders”. In this group, 125 were randomized to receive hydrocortisone and 108 received placebo. The demographic and clinical characteristics of patients in each group were similar. Over 90% of patients in each group were vented and all were receiving vasopressors, the most common being norepinephrine. With respect to the primary outcome, there was no significant difference in the rate of death at 28 days between the study groups. For the secondary end points, there was also no significant difference in the rate of death in “responders”, duration of ICU or hospital length of stay, or death at 1 year. The only difference that was found in those receiving hydrocortisone was a reduction in the time to reversal of shock. Importantly, this did not translate into improved mortality. Lastly, the authors reported an increase in new episodes of sepsis and septic shock in those receiving hydrocortisone but the absolute numbers are small.
Things to Consider: Investigators had planned to enroll 800 patients but stopped at 499 due to slow recruitment, termination of funding, and expiration of the study drug. In addition, the mortality rate in the placebo group was lower than what would be expected. As a result, the study is inadequately powered. In contrast to the Annane study, enrollment of patients could be up to 72 hours after the onset of shock, raising the question of timing of steroids administration. Furthermore, the majority of patients in this study were older, Caucasian males who required emergency surgery – not typical of the septic shock population at UMMC. Importantly, patients who were receiving long-term corticosteroids within the past 6 months, or short-term steroids within the past 4 weeks, were excluded – the patients we would typically give stress dose steroids to during refractory shock.
Take Home Point: Although CORTICUS is underpowered, it is one of the largest trials to date on corticosteroids in patients with septic shock. The results indicate that corticosteroid therapy in this patient population of “non-responders” had no effect on mortality. Based upon this study, the latest version of the Surviving Sepsis Campaign Guidelines has downgraded their recommendation on corticosteroids. It appears that the pendulum regarding steroids may now be swinging back in the negative direction.
Intensive insulin therapy and pentastarch resuscitation in severe sepsis.
Brunkhorst FM, Engel C, Bloos R, Meier-Hellmann A, Ragaller M, et al. NEJM 2008;358:125-139.
The concept of “tight glucose control” in critically ill patients primarily began with the Van de Berghe study in 2001. In this study, investigators found a reduction in mortality in critically ill patients whose glucose was maintained between 80 – 110 mg/dL. (Van de Berghe G, et al. NEJM 2001;345:1359-67.) The benefit was primarily seen in cardiac surgery patients who had multiple organ failure from sepsis. Furthermore, these patients were given a high glucose challenge immediately after surgery – not a common practice. More recently, the same investigators evaluated MICU patients who had not undergone surgery nor received a glucose challenge. (Van de Berghe G, et al. NEJM 2006;354-449-61.) In this latter study there was no benefit to intensive insulin therapy.
The current study is a multicenter, randomized, open-label study of both intensive insulin therapy and hydroxyethyl starch in patients with severe sepsis. The study was conducted from April 2003 to June 2005 in 18 multidisciplinary ICUs at academic tertiary hospitals in
The insulin arm of the study compared intensive insulin therapy to conventional insulin therapy. In the conventional group, insulin was given when glucose values were > 200 mg/dL, with the goal of maintaining glucose between 180 – 200 mg/dL. In the intensive insulin group, insulin was given when glucose values were > 110 mg/dL, with the goal of maintaining glucose between 80 – 110 mg/dL. Treatment ended at either discharge from the ICU, death, or a total of 21 days of therapy were reached.
Five hundred thirty seven patients were enrolled, 290 in the conventional insulin group and 247 in the intensive insulin group. Baseline patient characteristics including age, pre-existing co-morbidities, sites of infection, lab values, and hemodynamic variables were similar between the groups. Total nutritional intake, including glucose, was similar in both groups. Interestingly, the majority of patients had nosocomial acquired infections and over 60% in both groups were given hydrocortisone. Overall, there was no significant difference in the rate of death between the intensive and conventional insulin therapy groups. Furthermore, there was no significant difference in morbidity between the two groups. As one might expect, there was significantly more hypoglycemic episodes in the intensive insulin therapy group (17% vs. 4.1%). Although no deaths were attributable to hypoglycemia, there were more “life threatening” episodes of hypoglycemia in the intensive insulin group. As a result of the increase in hypoglycemic episodes the study was stopped early.
Take Home Point: In this patient population with severe sepsis, intensive insulin therapy, using a continuous infusion, to maintain glucose between 80 – 110 mg/dL did not improve mortality. It did, however, result in significantly more hypoglycemic episodes (glucose < 40 mg/dl). Many EDs across the country are now developing and implementing sepsis protocols primarily based upon the SSC Guidelines. Based upon this study, intensive insulin therapy may not be a necessary component to the ED management of patients with severe sepsis or septic shock.